^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Kanjinti (trastuzumab-anns) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
KANJINTI is a HER2/neu receptor antagonist indicated for: the treatment of HER2 overexpressing breast cancer.
Secondary therapy:
paclitaxel; paclitaxel + doxorubicin hydrochloride + cyclophosphamide; carboplatin + docetaxel; docetaxel + doxorubicin hydrochloride + cyclophosphamide
